The launch is growing—but manufacturing misses are already costing revenue

The quarter missed the market’s financial bar. Published expectations were roughly $12.4 million of revenue and a $(0.23) per-share loss; Abeona delivered $11.4 million and a $(0.35) loss.

Commercial momentum was real but not enough to offset the miss. Five patients were treated during the quarter and reported revenue increased 31% from Q1, but revenue was recognized for only four treatments because one manufacturing batch failed to produce enough sheets for recognition. Since launch, two additional patients generated no revenue because of low yield or failed lot-release specifications (Commercial update).

Manufacturing reliability is the buried negative. The treatment count suggests demand is developing, but the gap between patients treated and revenue recognized shows that production execution—not just patient onboarding—remains a constraint. That makes the reported $11.4 million less clean than the headline sequential growth implies.

CMS reimbursement creates a genuine offset, but it is future-facing. ZEVASKYN will receive New Technology Add-On Payment status beginning October 1, 2026, which could help hospitals adopt the therapy and improve Medicare access; Medicare patients represent about 10% of the addressable RDEB population (Commercial update). It supports the next leg of launch execution, but does not repair the current-quarter revenue or EPS shortfall.

Net: a launch that is progressing, but below the market’s near-term financial expectation. Lower R&D and SG&A spending helped operating expenses, yet the quarter still produced a larger loss and cash fell to $146.8 million. The filing therefore reads as operationally encouraging in direction, but a clear earnings miss with manufacturing execution still unresolved.